WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999040933) USE OF HYALURONIDASE TO REDUCE VISCOELASTIC RELATED INCREASES IN INTRAOCULAR PRESSURE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/040933    International Application No.:    PCT/US1999/003125
Publication Date: 19.08.1999 International Filing Date: 12.02.1999
IPC:
A61K 38/47 (2006.01)
Applicants: THE SCHEPENS EYE RESEARCH INSTITUTE, INC. [US/US]; 20 Staniford Street Boston, MA 02114 (US) (For All Designated States Except US).
REFOJO, Miguel, F. [US/US]; (US) (For US Only).
HAROONI, Mark [US/US]; (US) (For US Only).
FREILICH, Jonathan, M. [US/US]; (US) (For US Only).
ABELSON, Mark, B. [US/US]; (US) (For US Only)
Inventors: REFOJO, Miguel, F.; (US).
HAROONI, Mark; (US).
FREILICH, Jonathan, M.; (US).
ABELSON, Mark, B.; (US)
Agent: HEINE, Holliday, C.; Weingarten, Schurgin, Gagnebin & Hayes LLP Ten Post Office Square Boston, MA 02109 (US)
Priority Data:
60/074,837 17.02.1998 US
Title (EN) USE OF HYALURONIDASE TO REDUCE VISCOELASTIC RELATED INCREASES IN INTRAOCULAR PRESSURE
(FR) UTILISATION DE HYALURONIDASE AFIN DE DIMINUER LES HAUSSES DE PRESSION INTRAOCULAIRE ASSOCIEES A LA VISCOELASTICITE
Abstract: front page image
(EN)Small doses, less than 15 IU and preferably less than 10 IU per treated eye, of hyaluronidase can safely and effectively be employed to reduce postoperative intraocular pressure caused by residual amounts of hyaluronan used during anterior segment surgical procedures. The hyaluronidase may be administered after surgery, or at 5 IU or less per treated eye concomitantly. Hyaluronidase treatment may be combined with treatments with other medications.
(FR)On peut utiliser efficacement et sans danger des doses limitées, inférieures à 15 IU et, de préférence, inférieures à 10 IU par oeil traité, de hyaluronidase afin de diminuer la pression intraoculaire postopératoire provoquée par des quantités résiduelles de hyaluronan utilisé pendant des opérations chirurgicales du segment antérieur. On peut administrer hyaluronidase après l'intervention chirurgicale ou en raison d'une dose égale ou inférieure à 5 IU par oeil traité de façon concomitante. On peut combiner le traitement par hyaluronidase avec des traitements mettant en application d'autres médications.
Designated States: AU, CA, JP, US.
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)